Health Professionals  /  Chronic lymphocytic leukemia and prolymphocytic leukemia

Chronic lymphocytic leukemia and prolymphocytic leukemia

Indications

• 17p-: when initiation of treatment indicated, patient should received immuno-chemotherapy followed by first line allogeneic SCT.
• Recurrent disease < 12 months post fludarabine based treatment
• Recurent disease < 24 months post combined immuno-chemotherapy (ex.: RF, RFC, FC)

Eligibility

• Related transplant: < 66 years
• Unrelated transplant: < 61 years

Pre-transplant chemotherapy

• 17p: non bulky disease (< 5cm) Campath; bulky disease FCR followed by Campath if persistence of significant disease
• Without 17p: FCR unless progressive disease within 12 months of FCR